Sarah Klein, PhD, is the Associate Director of the Multiplex Assays Group at CST. This group was instrumental in the development and validation of SignalStar Multiplex IHC. Dr Klein has been with CST for seven years developing antibody-based solutions in the fields of immunology and oncology. She performed her postdoctoral research at Dana Farber Cancer Institute in Boston, MA, and her doctoral research at MD Anderson Cancer Center in Houston, TX, studying the mechanisms of action for immunotherapeutics used in the treatment of cancer, particularly glioblastomas.
